News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Achira is engaged in development and commercialization of PoC medical test kits in India
The company has posted net profit of Rs. 405.31 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs. 14.23 crores for the Financial Year ended March 31, 2024
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
